Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Women suffering from endometriosis experience severe pelvic pain and may suffer from infertility. Endometrial-like cells develop outside the uterine cavity. These cells are influenced by hormonal changes and respond similarly to the cells lining the uterus. Causes of endometriosis remain unknown and treatments are limited to either surgery or the use of hormonal drugs.

Q: Hello Krina. What is endometriosis and what causes this complex disorder?

KZ: Endometriosis is a women's health condition affecting many women in their reproductive years. It can cause severe pelvic pain and infertility, and is caused essentially by cells which normally line the uterus, the endometrium, ending up in other sites outside of the uterus, mainly the pelvis, appearing on pelvic organs. These cells respond to hormones, which normally happens in the menstrual cycle, but in other sites of the pelvis they can cause small bleeds, adhesions etc; and it is those kinds of deposits which can cause the symptoms that women experience - very bad period pain, pain at other times and infertility as well. We don't actually know what causes it. One of the main hypotheses is that the cells appear in the abdomen by a process called 'retrograde menstruation'- when some of the menstruation debris ends up in the pelvis. This happens in a lot of women but what we don't know is why in women with endometriosis these cells are still able to adhere to the pelvic wall and actually grow.

Q: How common is this disorder in the UK?

KZ: We don't know exactly because women have to undergo surgery to see if they have the condition or not. So we don't really know in the general population but we estimate it affects about 5% of women in reproductive age, which in the UK alone would be around about a million women. To give a comparison, that is similar in terms of frequency to conditions such as asthma. So it is really common and we have no reason to believe that in other countries that figure would be any different; we are talking about millions of women in the world.

Q: Can we cure this illness?

KZ: Currently the only way to treat this condition is in one of two ways: one is through surgery- actually trying to get rid of these lesions. That's the only way you can get rid of the disease. Currently what we don't really know is in how many women the disease grows back after that. The other way of treatment is medical treatment - hormonal treatment, that produces essentially a lessening of symptoms but once you stop medication, endometriosis tends to come back. Currently we have no definite way of curing the condition.

Q: How could a better understanding of endometriosis, genetic and environmental epidemiology help us develop therapeutic options?

KZ: What we are trying to do here is to find genes that are implicated in increasing the risk of endometriosis. We know that endometriosis can run in families - this is why we're doing this research - and at the same time we're trying to see whether those genes interact in some way with environmental risk factors. We are in the relatively early stages but what we're trying to do is see if particular genes that increase your risk of endometriosis tell us something about the pathway of disease, the biology of the disease and might give us new targets for drug development.

Q: What have been the most important lines of research development in the last 5-10 years in this area?

KZ: There's been a lot of work in the last 5-10 years and as funding has increased in the last couple of years - which has been fantastic - we've been able to really further some of the work on the condition. But there is still a lot to be done. One of the major lines of work is trying to find out whether there are any what we call 'biomarkers' of the condition that we could measure. For example currently the only way to diagnose a woman with the condition is for her to undergo surgery. It would be much better if there could be a blood test for a woman to be diagnosed. Worldwide there is quite a lot of work going into trying to find particular proteins in blood or in other tissues that could distinguish women with endometriosis from those without. That's one important line of research. I think another important line which is often forgotten is to actually show the public health impact of the condition. I think it's a condition that's often ignored by the public, but women as well. I think the kind of symptoms that women experience are often seen as something that's 'part of being a woman' so a lot of women suffer in silence in that sense. Trying to raise public awareness of the condition for them to seek earlier help, for them to be diagnosed earlier, all helps. One study we are currently doing is a global study trying to look at the impact of the condition worldwide in about 15 different centres across the world. Hopefully that will also raise awareness and show what an important condition it is not just here in the UK or in western countries but worldwide.

Q: My final question today is how does your research fit into translational medicine within the department?

KZ: We're currently at the early stages of trying to find the genes that are involved in endometriosis. Once we have a better handle on that hopefully it will tell us more about the biological pathways that are involved and hopefully that will give for example pharmaceutical industries some targets that they could work on for drug development. But also within the department, there might be other researchers that could help us to translate this into a better treatment of women, and maybe prevention as well, which I think will be the best thing of all.

Krina Zondervan

Women's health Conditions

Professor Krina Zondervan is interested in women's health conditions, particularly endometriosis. In women suffering from endometriosis, cells similar to those lining the uterus appear and flourish in areas outside the uterine cavity. Professor Zondervan studies genetic, molecular and environmental factors influencing this complex disorder.

More podcasts related to Genetics

Anna Gloyn: Genetics and Diabetes

Predictions suggest that by 2030, 366 million people worldwide will be affected by diabetes, a disease which already uses 10% of the NHS budget. Continued breakthroughs in the area of genetics related to different types of diabetes enable better diagnosis and treatment for patients and identify novel pathways that can be targeted for therapeutic interventions.

Erika Mancini: Chromatin Remodelling

Chromatin plays an important role in the regulation of gene expression. The movement of nucleosomes, packing and unpacking DNA, is governed by chromatin remodelling ATPases. Malfunctions in the regulation of chromatin structure often leads to complex multi-system diseases and cancer, notably leukemia.

Diabetes and Genomics by Mark McCarthy

Diabetes and obesity are both major challenges for global healthcare, with the social, health and economic costs over the next fifty years being in the ‘trillions’ of dollars. Genetics is one of the more important tools for developing a systematic understanding of the disease and how best to treat it in different patients.

Silvia Paracchini: Dyslexia and Genetics

Dyslexia is an impairment in learning to read that affects up to 10% of children; it can have profound effects on an individual life. Dyslexia has an important genetic component; candidate genes control important stages during foetal brain development. Understanding the biology of dyslexia could help us design more effective diagnostic criteria and treatment plans.

Claire Palles: Gastrointestinal cancers

The gastrointestinal track is responsible for more cancers than any other system. A condition called Barrett's oesophagus, characterised by a change in the cells lining the oesophagus, can lead to oesophageal adenocarcinoma. Only few people with Barrett's oesophagus will go on to develop cancer, and genome sequencing studies aim to identify genetic risk factors and therefore better target high-risk patients.

Antonio Velayos-Baeza: Rare neurological disorders

ChAc is a rare progressive neurological disorder caused by mutations in a very complex gene. A better understanding of the biology underlying this disease helps develop better diagnostic tools, and opens up the possibility of discovering targets for possible future treatments.

Zamin Iqbal: Computation and genetics

Resistance to drugs in bacteria can be aquired by swapping genes between individual bacteria. Computer programs developed by Dr Iqbal enable doctors to predict which antibiotics will be met with drug resistance, enabling the selection of the right drug. His work also enables the tracking of an infection from patient to patient, as well as the tracking of the spread of an infection within a hospital.

Gerton Lunter: The evolution of the genome

Computational and stastistical methods help us understand evolution as well as genetic disease. Looking at our genomes opens up clinical possibilities, for example in cancer, allowing more genes to be looked at - more quickly and more cheaply, wich can impact prognosis and treatment selection.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Christopher Yau: Big Data

Over the past decade, data-driven science has produced enormous sets of data. The convergence of statistics and computer science, in the field known as machine learning, provide the means to understand these large datasets. Ultimately, machine learning algorithms will be develop into clinical decision making support systems.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.